RCT of Gastric ESD With or Without Epineprhine Added Solution

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-10

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an international multi-center randomised controlled study comparing outcomes of gastric endoscopic submucosal dissection (ESD) with or without addition of epinephrine in the submucosal injection solution.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

NCT06722664

Gastric Mucosal Lesion

ACTIVE_NOT_RECRUITING PHASE2

Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD

NCT02407119

Helicobacter Pylori Infection Early Gastric Cancer Endoscopic Resection

ACTIVE_NOT_RECRUITING PHASE3

The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology

NCT04029441

Helicobacter Gastritis

UNKNOWN

The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Gastric Cancer and Related Diseases

NCT07332104

Gastric Cancer (GC) Gastric Cancer (Diagnosis)

NOT_YET_RECRUITING

AG & IM in CA Stomach Protocol

NCT04184960

Gastric Cancer Atrophic Gastritis Intestinal Metaplasia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Endoscopic submucosal dissection (ESD) is an endoscopic technique aiming to achieve en-bloc resection of mucosal neoplastic lesion in the gastrointestinal tract. It is now considered as the standard of treatment for early gastric cancer confined to the mucosa, achieving an excellent overall survival comparable to that of surgical resection.

Important adverse events associated with gastric ESD include hemorrhage (intraoperative or delayed) and perforation. The reported incidence of intraprocedural and delayed hemorrhage of gastric ESD is generally higher than that of esophageal or colorectal ESD5. This is likely due to the rich blood supply of the stomach penetrating from the muscularis to the submucosal layer. Bleeding during ESD would result in difficulty in visualizing the correct plane of dissection from blood clots obscuring view of the endoscope. As a result, prolonged procedural time may be required to achieve hemostasis and obtain adequate view for dissection.

There are currently different options of the solution for submucosal injection during gastric ESD. Epineprhine has often been added into these solutions with the aim of causing vasoconstrictive effect and potentially reduce bleeding during the procedure. The use of epinephrine has been recommended when removing larger pedunculated polyps with endoscopic mucosal resection (EMR)6. However the exact clinical benefit of adding epinephrine during gastric ESD has not been proven in the literature. On the other hand, when larger dose of epinephrine is absorbed systemically it may rarely cause significant tachycardia and generalized vasoconstriction, putting patients at risk of myocardial infarction or cerebrovascular accident.

A retrospective propensity score analysis was previously performed in one of our Japanese center (Presented at JGCA 2019, Shizuoka). After adjustment of important confounding factors including age, sex, tumor location, specimen size, depth of tumor invasion, presence of histological ulcer or scar and operators' experience, the addition of epinephrine into submucosal solution was associated with a significantly shorter procedural time upon multivariate analysis. The mean procedural time was 72±54 minutes versus 93±62 minutes with and without epinephrine respectively. (p\<0.001) With the encouraging result from a single center retrospective study, we plan to conduct a prospective multicenter randomized controlled study to confirm the benefit of adding epinephrine into the submucosal solution during gastric ESD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Neoplasm Early Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Epinephrine

0.2ml 1:10000 epinephrine diluted into each 20ml of the original solution for submucosal injection

Group Type EXPERIMENTAL

Endoscopic submucosal dissection

Intervention Type PROCEDURE

Endoscopic submucosal dissection

Epinephrine

Intervention Type DRUG

Epinephrine

Non-epinephrine

No epinephrine would be added into the solution

Group Type ACTIVE_COMPARATOR

Endoscopic submucosal dissection

Intervention Type PROCEDURE

Endoscopic submucosal dissection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endoscopic submucosal dissection

Intervention Type PROCEDURE

Epinephrine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Selection criteria: Presence of intramucosal neoplastic lesions in the stomach planning for endoscopic submucosal dissection (Vienna Classification Category 3 and 4 lesion)
* Target subjects receiving sufficient briefing from the attending physician regarding the content of this study and providing informed consent for participation

Exclusion Criteria

* Recurrent / remnant lesion after previous endoscopic resection
* Lesions arising from surgical anastomotic site, such as gastrojejunostomy / gastroduodenostomy.
* Marked electrolyte abnormalities
* Hemostatic or coagulative abnormalities
* Patient on anti-coagulant agents, including warfarin and other direct oral anti-coagulants (those on antiplatelet can be included)
* Failure of vital organ (heart, lungs, liver, or kidneys) function
* Allergic to components of injection solutions: Epinephrine, hyaluronic acid etc
* Other cases deemed by the examining physician as unsuitable for safe treatment

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No